Morgan Stanley Sees Big Potential in Kalaris’ Eye Drug TH103
Kalaris Therapeutics gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients.
/ 2 items
Kalaris Therapeutics gets a boost as Morgan Stanley backs its longer-lasting eye drug, cutting injections for patients.
Kalaris Therapeutics (KLRS) secured $50 million in oversubscribed funding at a premium to support its eye drug, TH103. However, small trials, safety concerns, and lengthy timelines create uncertainty.